Candel Therapeutics (CADL)
9.86
0.00 (0.00%)
Upcoming Events
Latest Headlines
Stifel Starts Candel Therapeutics Inc. (CADL) at Buy
July 13, 2026 2:13 AM - StreetInsider
Form 4 Candel Therapeutics, For: Jul 06 Filed by: Sims Mark E.
July 8, 2026 4:13 PM - SEC Filing
Form 3 Candel Therapeutics, For: Jul 06 Filed by: Sims Mark E.
July 8, 2026 4:11 PM - SEC Filing
Candel Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
July 8, 2026 4:05 PM - StreetInsider
Form 4 Candel Therapeutics, For: Jun 29 Filed by: Barone Francesca
July 1, 2026 4:23 PM - SEC Filing
Form 4 Candel Therapeutics, For: Jun 29 Filed by: Tyagarajan Seshu
July 1, 2026 4:22 PM - SEC Filing
Form 4 Candel Therapeutics, For: Jun 30 Filed by: Manning Paul B
July 1, 2026 4:21 PM - SEC Filing
Form 4 Candel Therapeutics, For: Jun 30 Filed by: PAPA JOSEPH C
July 1, 2026 4:21 PM - SEC Filing
Form 4 Candel Therapeutics, For: Jun 30 Filed by: Loggia Nicoletta
July 1, 2026 4:20 PM - SEC Filing
Candel Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
July 1, 2026 4:05 PM - StreetInsider
Candel Therapeutics launches phase 3 lung cancer trial for CAN-2409
June 30, 2026 8:05 AM - StreetInsider
Candel Therapeutics Announces Initiation of Global Pivotal Phase 3 AURORA Trial Evaluating Aglatimagene Besadenovec (CAN-2409) in Advanced Non-Small Cell Lung Cancer Patients with Inadequate Response
June 30, 2026 8:05 AM - StreetInsider
Form 144 Candel Therapeutics, Filed by: Tyagarajan Seshu
June 29, 2026 4:44 PM - SEC Filing
Form 144 Candel Therapeutics, Filed by: Barone Francesca
June 29, 2026 4:42 PM - SEC Filing
Candel Therapeutics names Mark Sims as chief commercial officer
June 25, 2026 8:05 AM - StreetInsider
Candel Therapeutics Appoints Mark Sims as Chief Commercial Officer
June 25, 2026 8:05 AM - StreetInsider
Form 4 Candel Therapeutics, For: Jun 23 Filed by: Radhakrishnan Maha
June 24, 2026 4:36 PM - SEC Filing
Form 4 Candel Therapeutics, For: Jun 23 Filed by: Loggia Nicoletta
June 24, 2026 4:35 PM - SEC Filing
Form 4 Candel Therapeutics, For: Jun 23 Filed by: PAPA JOSEPH C
June 24, 2026 4:34 PM - SEC Filing
Form 4 Candel Therapeutics, For: Jun 23 Filed by: Benz Edward J. JR
June 24, 2026 4:32 PM - SEC Filing
Form 4 Candel Therapeutics, For: Jun 23 Filed by: Martell Christopher
June 24, 2026 4:31 PM - SEC Filing
Form 4 Candel Therapeutics, For: Jun 23 Filed by: Gaeta Renee
June 24, 2026 4:31 PM - SEC Filing
Form 4 Candel Therapeutics, For: Jun 23 Filed by: Nabel Gary J.
June 24, 2026 4:28 PM - SEC Filing
Form 4 Candel Therapeutics, For: Jun 23 Filed by: Nguyen Diem
June 24, 2026 4:27 PM - SEC Filing
Form 4 Candel Therapeutics, For: Jun 23 Filed by: Manning Paul B
June 24, 2026 4:27 PM - SEC Filing
Form 8-K Candel Therapeutics, For: Jun 23
June 24, 2026 4:24 PM - SEC Filing
Form 8-K Candel Therapeutics, For: Jun 12
June 16, 2026 4:24 PM - SEC Filing
Candel publishes phase 3 prostate cancer trial data in Lancet Oncology
June 2, 2026 8:05 AM - StreetInsider
Candel Therapeutics Announces Publication in The Lancet Oncology of Pivotal Phase 3 Data Demonstrating Significant Improvement in Disease-Free Survival with Aglatimagene Besadenovec (CAN-2409) in Loca
June 2, 2026 8:05 AM - StreetInsider
Candel Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
June 1, 2026 4:05 PM - StreetInsider
Candel Therapeutics Inc. (CADL) PT Raised to $9 at BofA Securities
May 18, 2026 3:22 PM - StreetInsider
Form 8-K Candel Therapeutics, For: May 15
May 15, 2026 4:19 PM - SEC Filing
Candel Therapeutics reports extended clinical benefits in phase 3 prostate cancer trial
May 15, 2026 4:05 PM - StreetInsider
Candel Therapeutics Reports Extended Clinical Benefit Over Multiple Clinical Endpoints in Patients from Phase 3 Trial of Aglatimagene Besadenovec (CAN-2409) in Localized Prostate Cancer Under Prolonge
May 15, 2026 4:05 PM - StreetInsider
Form SCHEDULE 13G Candel Therapeutics, Filed by: RTW INVESTMENTS, LP
May 15, 2026 8:09 AM - SEC Filing
Form 10-Q Candel Therapeutics, For: Mar 31
May 14, 2026 8:31 AM - SEC Filing
Candel Therapeutics, Inc. (CADL) Tops Q1 EPS by 20c
May 14, 2026 8:28 AM - StreetInsider
Form 8-K Candel Therapeutics, For: May 14
May 14, 2026 8:15 AM - SEC Filing
Candel Therapeutics Reports First Quarter 2026 Financial Results and Recent Corporate Highlights
May 14, 2026 8:05 AM - Globe NewsWire
Candel Therapeutics to Present at Upcoming Investor Conferences
May 13, 2026 8:05 AM - Globe NewsWire
Candel Therapeutics schedules call on prostate cancer trial data
May 4, 2026 8:05 AM - StreetInsider
Candel Therapeutics to Host Investor Conference Call Following Presentation of Extended Data from Phase 3 Trial of Aglatimagene Besadenovec in Localized Prostate Cancer at the American Urological Asso
May 4, 2026 8:05 AM - Globe NewsWire
Candel Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
May 1, 2026 4:05 PM - StreetInsider
Form ARS Candel Therapeutics, For: Dec 31
April 29, 2026 4:14 PM - SEC Filing
Form DEFA14A Candel Therapeutics,
April 29, 2026 4:12 PM - SEC Filing
Form DEF 14A Candel Therapeutics, For: Jun 23
April 29, 2026 4:07 PM - SEC Filing
Candel Therapeutics partners with EVERSANA for drug commercialization
April 29, 2026 8:05 AM - StreetInsider
Candel Therapeutics Announces Commercialization Agreement with EVERSANA to Support Potential U.S. Launch of Aglatimagene Besadenovec in Localized Prostate Cancer
April 29, 2026 8:05 AM - Globe NewsWire
Form SCHEDULE 13G/A Candel Therapeutics, Filed by: BlackRock, Inc.
April 27, 2026 4:14 PM - SEC Filing
Full Article List
